pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

56 catalysts · 16 phase 2 completion · 10 phase 1 completion · 8 phase 2 initiation · 4 phase 1 2 completion · 4 phase 1 initiation · 4 phase 0 trial completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: psoriasis×TA: cardiology×TA: pulmonology×clear all
type
  • phase 2 completion16
  • phase 1 completion10
  • phase 2 initiation8
  • phase 1 2 completion4
  • phase 1 initiation4
  • phase 0 trial completion4
  • phase 3 initiation3
  • phase 3 completion2
  • phase iv trial initiation1
  • drug expiry1
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    10
    ›Apr 24, 2026patent expiry90d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry90d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoPeople's College of Medical Sciences & Research Centre — formoterol (Phase IV Trial Initiation)formoterol

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →formoterol →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoNational Institute of Siddha — undisclosed siddha medicine (Phase II Trial Completion)undisclosed siddha medicine

    Therapy area: Respiratory. Indication: Asthma

    full page →undisclosed siddha medicine →source: globaldata
    ›Apr 26, 2026phase 1 2 completion88d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Cardiovascular. Indication: Thrombophlebitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 2 initiation88d agoStarmab Biology (Suzhou) Co Ltd — XJ-103 (Phase II Trial Initiation)XJ-103

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →XJ-103 →source: globaldata
    ›Apr 26, 2026phase 2 results88d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →artichoke →source: globaldata
    ›Apr 26, 2026phase 3 completion88d agoHomi Bhabha Cancer Hospital Research Centre — megestrol (Phase III Trial Completion)megestrol

    Therapy area: Central Nervous System, Gastrointestinal, Genito Urinary System, Respiratory. Indication: Anorexia Nervosa, Unspecified Gastrointestinal Disorders, Unspecified Genito Urinary Disorders, Unspecified Respiratory Disorders

    full page →megestrol →source: globaldata
    ›Apr 26, 2026phase 3 completion88d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

    Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

    full page →diltiazem →source: globaldata

    Week of Apr 27, 2026

    40
    ›Apr 27, 2026phase 2 initiation87d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation
    ← prev
    page 1 of 2
    next →
    87d ago
    Mahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation87d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 3 initiation87d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase 3 initiation87d agoGan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)bofanglutide

    Therapy area: Respiratory. Indication: Obstructive Sleep Apnea

    full page →bofanglutide →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 2 completion86d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 28, 2026phase 2 initiation86d agoInstitute of Medical Sciences of the Banaras Hindu University — ropivacaine (Phase II Trial Initiation)ropivacaine ER

    Therapy area: Central Nervous System, Respiratory. Indication: Pleural Disease, Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 28, 2026phase 2 initiation86d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 29, 2026phase 1 completion85d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 3 initiation85d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe84d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026phase 0 trial completion84d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion84d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion84d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

    Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

    full page →dantrolene →source: globaldata
    ›Apr 30, 2026phase 0 trial completion84d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

    full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata
    ›Apr 30, 2026phase 1 completion84d agoJiangxi Jemincare Group Co Ltd — JMKX-003142 (Phase I Trial Completion)JMKX-003142

    Therapy area: Cardiovascular, Genetic Disorders. Indication: Edema, Polycystic Kidney Disease

    full page →JMKX-003142 →source: globaldata
    ›Apr 30, 2026phase 1 completion84d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →pneumococcal (20-valent) vaccine →source: globaldata
    ›Apr 30, 2026phase 1 completion84d agoJiangsu Postgraduate Research and Practice Innovation Program — acetaminophen (Phase I Trial Completion)acetaminophen ER

    Therapy area: Cardiovascular. Indication: Patent Ductus Arteriosus

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 completion84d agoPhrae Hospital — bupivacaine (Phase I Trial Completion)bupivacaine

    Therapy area: Cardiovascular, Central Nervous System, Gastrointestinal. Indication: Hypotension, Post Operative Nausea And Vomiting, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 1 completion84d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

    Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

    full page →undisclosed Covid-19 vaccine →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

    full page →enoxaparin sodium biosimilar →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

    Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

    full page →DAPAGLIFLOZIN →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

    Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

    full page →deferiprone →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

    Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

    full page →Atibuclimab →source: globaldata
    ›Apr 30, 2026phase 1 2 completion84d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

    Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

    full page →polyphenol-rich cocoa extract →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

    Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

    full page →centhaquine citrate →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

    Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

    full page →lenvatinib →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

    Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

    full page →apixaban ODT →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

    full page →Loberamisal →source: globaldata
    $CPIX7.1150-9.36%
    $MRK127.47+0.96%